- The SEC has declared the registration statement for the merger between Helix Acquisition Corp. II (HLXB, Financial) and BridgeBio Oncology Therapeutics (BBOT) effective.
- The shareholder vote for the merger is scheduled for August 4, 2025, with the anticipated closing of the transaction later that month.
- The combined company will be renamed "BridgeBio Oncology Therapeutics" and will focus on developing small molecule therapeutics for cancer.
Helix Acquisition Corp. II (HLXB) and BridgeBio Oncology Therapeutics (BBOT) have announced that the U.S. Securities and Exchange Commission (SEC) has declared effective their registration statement for the proposed business combination. This crucial regulatory milestone paves the way for a merger set to be finalized pending the approval of Helix shareholders at an extraordinary general meeting on August 4, 2025.
BridgeBio Oncology Therapeutics, originally a subsidiary of BridgeBio Pharma (BBIO), is a clinical-stage biopharmaceutical entity developing innovative treatments targeting RAS and PI3K? malignancies, addressing significant medical needs in oncology. The merger will transition BBOT into an independent, publicly-traded company under the new name "BridgeBio Oncology Therapeutics."
Helix Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, had raised $184 million during its IPO in February 2024. This SPAC structure offers BBOT a strategic path to public markets, enhancing access to capital and aligning with specialized life sciences investors.
Upon closing, the merger is expected to drive the continued development of BBOT's promising pipeline, which includes clinical trials such as ONKORAS-101 and BREAKER-101, and compounds like BBO-8520, BBO-10203, and BBO-11818. These assets highlight a diverse approach to therapeutics targeting some of the most prevalent oncogenes in human cancers.
For existing Helix shareholders, the upcoming meeting represents a pivotal decision point. Approving the merger will facilitate the transformation of BBOT into a standalone company with a focus on enhancing cancer treatment outcomes, while also leveraging the benefits offered by public market entry.
